‘Studies showed that 20% of cats with HCM have resistance to clopidogrel therapy. The reason behind this is the genetic makeup of cats which determines the way that they could respond to different treatments for blood clots due to heart disease.’
Veterinarians at the University of California have performed a clinical trial on cats with HCM. They tested the blood clot forming capacity among these cats and then administered clopidogrel for two weeks. When the cats were subjected to genetic tests that detect mutations, the team found that the genetic makeup of cats alters how they respond to different therapies that prevent blood clots due to HCM.
This research has created a foundation for personalized therapies for pets that would allow veterinarians in earlier treatment decisions. “We are very excited to be approaching this era where personalized or precision medicine in animals can catch up to precision medicine in humans,” added Ronald.
Source: Medindia
